Sangamo Therapeutics, Inc

Approval AI-extracted

isaralgagene civaparvovec

Fabry disease

Date

TBD

Approval decision · Date TBD estimated

What's at stake A final FDA approval decision on isaralgagene civaparvovec for Fabry disease is expected Date TBD.

Primary source · SEC 8-K verified 14h ago

“The FDA has recently affirmed to us that two-year eGFR data may serve as confirmatory evidence for traditional approval.”